Soy Supplementation and Gestational Diabetes

Overview

The purpose of this study is to assess the feasibility of randomizing pregnant women at high risk for gestational diabetes to a 24-week period of soy food consumption. This study will also examine the effects of soy protein and isoflavones on glucose metabolism and lipid levels among pregnant women at high risk for gestational diabetes, and on child's weight and height at birth and 6 weeks of life.

Full Title of Study: “A Pilot Study of Soy Protein and Isoflavone Supplementation for Improved Glucose Metabolism and Lipid Profiles in Pregnant Women at High Risk for Gestational Diabetes Mellitus (GDM)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2016

Detailed Description

Evidence from animal studies, human observational studies, and some randomized controlled trials has suggested that soy protein and isoflavones have beneficial effects on lipid and glucose metabolism. Additionally, soy isoflavones can diffuse across the placenta, enter fetal circulation and potentially reduce the susceptibility to cardiometabolic disorders in adulthood. Given the high prevalence of GDM and its serious health consequences for women and their children, and likely health benefits of soy protein and isoflavones on a panel of metabolic parameters, the role of maternal supplementation of soy protein and isoflavones for prevention of GDM and/or minimization of GDM severity in mothers and for improving health indicators in their offspring merits investigation. This study will provide new and essential information about the efficacy and feasibility of using soy-based whole foods to prevent and manage gestational diabetes development. This study will be a randomized, placebo-controlled trial. Forty pregnant women at high risk for gestational diabetes will be recruited from the obstetrics services at the Melrose Wakefield Hospital and Tufts Medical Center, and randomized to receive soy-based foods or minimize soy intake, from the 16th gestational week to birth. To measure participants' compliance with the treatment, the study will use three methods: (1) monthly telephone interview about adherence to the treatment; (2) daily soy food intake log; and (3) serum isoflavone concentrations. To evaluate the effects of soy supplementation on GDM, the study will collect blood samples to measure glucose, insulin, HbA1c, and lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol ). The study will also measure weight and body composition of participating pregnant women and the participants' respective children's weight, length and body composition.

Interventions

  • Dietary Supplement: Soy Group (Soy Protein + Isoflavones)
    • Women in the intervention group are asked to eat a combination of soy foods that contain about 25 grams of protein and 60-75 milligrams of isoflavones per day, from the 16th gestational week to birth. A registered dietitian will instruct them to incorporate the soy foods into their daily diet.
  • Dietary Supplement: Control Group (Minimize Soy Intake)
    • Women in the control group will be instructed by the dietitian how to avoid soy supplements and minimize soy intake.

Arms, Groups and Cohorts

  • Experimental: Soy Group (Soy Protein + Isoflavones)
    • Intervention: Soy-based whole foods containing about 25 grams of soy protein and 60-75 mg isoflavones. Intervention group will consume soy foods containing about 25 grams of soy protein and 60-75 mg isoflavones per day, from 16th gestational week to birth. Examples of soy foods that contain 25 grams of soy protein and 60-75mg isoflavones include: 2 cups of soy milk, or 12 ounces tofu, or a half cup of soy nuts. Women in the Soy Group will be instructed by a registered dietitian how to incorporate the soy foods into their daily diet.
  • Placebo Comparator: Control Group (Minimize Soy Intake)
    • Control Group will avoid soy supplements and minimize intake of soy foods.

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants With Adverse Events That Are Related to Treatment
    • Time Frame: From enrollment through study completion, an average of 30 weeks or 210 days.
    • The first aim of this study is to determine the safety of soy supplementation during pregnancy. This will be assessed by the number of participants who reported adverse events that are related to the study treatment.

Secondary Measures

  • Effects of Soy Intake on Triglycerides (TG)
    • Time Frame: Baseline (14 weeks of pregnancy), 28 weeks of pregnancy, and 6 week postpartum
    • The second aim of this study is to assess the effects of soy intake during pregnancy on glucose and lipid metabolism, and inflammation. Triglycerides (TG) is one of the measurements of lipid metabolism.
  • Effects of Soy Intake on Total Cholesterol (TC)
    • Time Frame: Baseline (14 weeks of pregnancy), 28 weeks of pregnancy, and 6 week postpartum
    • The second aim of this study is to assess the effects of soy intake during pregnancy on glucose and lipid metabolism, and inflammation. Total cholesterol (TC) is a measurement of lipid metabolism.
  • Effects of Soy Intake on High-density Lipoprotein Cholesterol (HDL-C)
    • Time Frame: Baseline (14 weeks of pregnancy), 28 weeks of pregnancy, and 6 week postpartum
    • The second aim of this study is to assess the effects of soy intake during pregnancy on glucose and lipid metabolism, and inflammation. High-density lipoprotein cholesterol (HDL-C) is a measurement of lipid metabolism.
  • Effects of Soy Intake on Free Fatty Acid (FFA)
    • Time Frame: Baseline (14 weeks of pregnancy), 28 weeks of pregnancy, and 6 week postpartum
    • The second aim of this study is to assess the effects of soy intake during pregnancy on glucose and lipid metabolism, and inflammation. Free fatty acid (FFA) is a measurement of lipid metabolism.
  • Effects of Soy Intake on Fasting Glucose
    • Time Frame: Baseline (14 weeks of pregnancy), 28 weeks of pregnancy, and 6 week postpartum
    • The second aim of this study is to assess the effects of soy intake during pregnancy on glucose and lipid metabolism, and inflammation. Fasting glucose is a measurement of glucose metabolism.
  • Effects of Soy Intake on Fasting Insulin
    • Time Frame: Baseline (14 weeks of pregnancy), 28 weeks of pregnancy, and 6 week postpartum
    • The second aim of this study is to assess the effects of soy intake during pregnancy on glucose and lipid metabolism, and inflammation. Fasting insulin is a measurement of glucose metabolism.
  • Effects of Soy Intake on Hemoglobin A1c (HbA1c)
    • Time Frame: Baseline (14 weeks of pregnancy), 28 weeks of pregnancy, and 6 week postpartum
    • The second aim of this study is to assess the effects of soy intake during pregnancy on glucose and lipid metabolism, and inflammation. Hemoglobin A1c (HbA1c) is a measurement of glucose metabolism.
  • Effects of Soy Intake on C-reactive Protein (CRP)
    • Time Frame: Baseline (14 weeks of pregnancy), 28 weeks of pregnancy, and 6 week postpartum
    • The second aim of this study is to assess the effects of soy intake during pregnancy on glucose and lipid metabolism, and inflammation. C-reactive protein (CRP) is a measurement of inflammation.

Participating in This Clinical Trial

Inclusion Criteria

  • Age >=18 years – ≤ 18 weeks of pregnancy – Singleton pregnancy – Have at least one of the risk factors for GDM, including overweight (BMI ≥ 25 kg/m2) before this pregnancy, first-degree relative with type-2 diabetes mellitus (T2DM), abnormal glucose tolerance/GDM in previous pregnancy, and/or history of macrosomia (birth weight ≥ 4,000 gram) in previous pregnancy – Being able and willing to give written informed consent. Exclusion Criteria:

  • Allergic to soy or milk products – Current smoker – Preexisting diabetes outside of pregnancy or other heath conditions that could affect glucose levels – Chronic or serious medical conditions such as hypertension, heart disease, stroke, chronic renal or hepatic disease, or malignant disease (by self-report and medical record review) – Use of medications that could interfere with insulin secretion or insulin sensitivity – Weight loss during this pregnancy more than 10% of pre-pregnancy body weight – Current severe nausea and/or vomiting (by self-report).

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Massachusetts, Boston
  • Collaborator
    • University of Massachusetts, Worcester
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ling Shi, PhD, Principal Investigator, University of Massachusetts, Boston

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.